

## Fellow Publications/Presentations January through December 2023

### Publications

1. **Hubben A**, McCrae KR. How to diagnose and manage antiphospholipid syndrome. *Hematology Am Soc Hematol Educ Program*. 2023 Dec 8;2023(1):606-613. doi: 10.1182/hematology.2023000493. PMID: 38066904; PMCID: PMC10727028.
2. **Hubben A**, **Dima D**, Atieh T, Chaulagain C, Faiman B, Ferraro C, Mazzoni S, Williams L, Samaras C, Valent J, Sauter C, Anwer F, Khouri J. On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone. *Bone Marrow Transplant*. 2023 May;58(5):610-612. doi: 10.1038/s41409-023-01938-0. Epub 2023 Feb 24. PMID: 36828957; PMCID: PMC10164067.
3. Alarabi A, **Hubben A**, Barnard J, Knight JS, McCrae KR. Transcriptome analysis suggests a central role for complement and C5aR1 in neutrophil activation in APS. *Thromb Res*. 2023 Oct;230:94-97. doi: 10.1016/j.thromres.2023.08.014. Epub 2023 Aug 30. PMID: 37660437.
4. **Muthusamy B**, Pennell NA. ADAURA update: only the end of the beginning. *Transl Lung Cancer Res*. 2023 Jul 31;12(7):1649-1651. doi: 10.21037/tlcr-23-237. Epub 2023 May 22. PMID: 37577316; PMCID: PMC10413021.
5. **Muthusamy B**, Raskina K, Lofgren KT, Li G, Tolba K, Schwed K, Castellanos E, Huang RSP, Oxnard GR, Schrock AB, Pennell N. Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma. *J Thorac Oncol*. 2023 Apr;18(4):476-486. doi: 10.1016/j.jtho.2022.11.027. Epub 2022 Dec 6. PMID: 36494074.
6. **Roof L**, Yilmaz E. Immunotherapy in HPV-Related Oropharyngeal Cancers. *Curr Treat Options Oncol*. 2023 Mar;24(3):170-183. doi: 10.1007/s11864-023-01050-x. Epub 2023 Jan 31. PMID: 36719604; PMCID: PMC9887557.
7. **Roof L**, Geiger JL. Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes. *Cancer Manag Res*. 2023 Apr 11;15:343-350. doi: 10.2147/CMAR.S348711. PMID: 37070083; PMCID: PMC10105566.
8. **Yalamanchali A**, Yang K, **Roof L**, **Lopetegui-Lia N**, Schwartzman LM, Campbell SR, Woody NM, Silver N, Koyfman S, Geiger JL, Yilmaz E. Comparison of real-world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials. *Head Neck*. 2023 Apr;45(4):862-871. doi: 10.1002/hed.27302. Epub 2023 Feb 20. PMID: 36806299.
9. **Schuster J**, Sheng IY, Reddy CA, Khorana AA, Nizam A, Gupta S, Gilligan T, Wee CE, Sussman TA, Bonham A, Maroli K, Martin A, Ornstein MC. Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2023 Oct 5:S1558-7673(23)00216-1. doi: 10.1016/j.clgc.2023.09.005. Epub ahead of print. PMID: 37932205.

10. **Brooks TR**, Jagadeesh D. Conditioning regimens: balancing efficacy and toxicity. *Leuk Lymphoma*. 2023 Jul-Aug;64(7):1223-1224. doi: 10.1080/10428194.2023.2239970. Epub 2023 Jul 28. PMID: 37501586.
11. **Brooks TR**, Caimi PF. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma. *Blood Rev*. 2023 Oct 28;101140. doi: 10.1016/j.blre.2023.101140. Epub ahead of print. PMID: 37949705.
12. Farha N, **Dima D**, Ullah F, Kamath S. Precision Oncology Targets in Biliary Tract Cancer. *Cancers (Basel)*. 2023 Mar 31;15(7):2105. doi: 10.3390/cancers15072105. PMID: 37046766; PMCID: PMC10093316.
13. Ullah F, **Dima D**, Omar N, Ogbue O, Ahmed S. Advances in the treatment of Hodgkin lymphoma: Current and future approaches. *Front Oncol*. 2023 Mar 3;13:1067289. doi: 10.3389/fonc.2023.1067289. PMID: 36937412; PMCID: PMC10020509.
14. **Dima D**, Ullah F, Mazzone S, Williams L, Faiman B, Kurkowski A, Chaulagain C, Raza S, Samaras C, Valent J, Khouri J, Anwer F. Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice. *Cancers (Basel)*. 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160. PMID: 37046821; PMCID: PMC10093129.
15. **Dima D**, Valent J, Khouri J. Daratumumab monotherapy for relapsed POEMS syndrome. *Am J Hematol*. 2023 Nov;98(11):E291-E294. doi: 10.1002/ajh.27050. Epub 2023 Aug 7. PMID: 37548551.
16. **Dima D**, Mazzone S, Anwer F, Khouri J, Samaras C, Valent J, Williams L. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation. *JCO Oncol Pract*. 2023 May;19(5):265-275. doi: 10.1200/OP.22.00396. Epub 2023 Feb 28. PMID: 36854070.
17. **Dima D**, Orland M, Ullah F, Anwer F, Mazzone S, Raza S, Chaulagain CP, Samaras C, Valent J, Williams L, Khouri J. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2023 Nov;23(11):857-860. doi: 10.1016/j.clml.2023.07.007. Epub 2023 Aug 1. PMID: 37558531.
18. **Dima D**, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, Shune L, Kaur G, Khouri J, Afrough A, Strouse C, Lochner J, Mahmoudjafari Z, Raza S, Valent J, Anderson LD Jr, Anwer F, Abdallah AO, Hashmi H. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience. *Transplant Cell Ther*. 2023 Dec 25:S2666-6367(23)01752-9. doi: 10.1016/j.jtct.2023.12.016. Epub ahead of print. PMID: 38151105.
19. **Dima D**, Li A, Granat LM, Dhillon P, Chamseddine F, Yalamanchali A, Mirzai S, Wei W, Samaras CJ, Valent J, Anwer F, Khouri J. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. *Br J Haematol*. 2023 Apr;201(2):280-284. doi: 10.1111/bjh.18630. Epub 2023 Jan 5. PMID: 36604838.
20. Davis JA, **Dima D**, Ahmed N, DeJarnette S, McGuirk J, Jia X, Raza S, Khouri J, Valent J, Anwer F, Abdallah AO, Hashmi H. Impact of Frailty on Outcomes After CAR T-cell Therapy for

Patients with Relapsed/Refractory Multiple Myeloma. *Transplant Cell Ther.* 2023 Dec 22;S2666-6367(23)01750-5. doi: 10.1016/j.jtct.2023.12.015. Epub ahead of print. PMID: 38142943.

21. Mishra R, **Dima D**, Kumar SA, Mian A, Taneja A, Karna R, Caimi PF, Hill BT, Dean R, Jagadeesh D. A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies. *Hematol Oncol.* 2023 Dec;41(5):884-893. doi: 10.1002/hon.3192. Epub 2023 Jun 13. PMID: 37309225.
22. Tran J, Thaper A, **Lopetegui-Lia N**, Ali A. Locoregional recurrence in triple negative breast cancer: past, present, and future. *Expert Rev Anticancer Ther.* 2023 Jul-Dec;23(10):1085-1093. doi: 10.1080/14737140.2023.2262760. Epub 2023 Oct 26. PMID: 37750222.
23. **Lopetegui-Lia N**, Dima D, Buchberger DS, Yalamanchali A, Osantowski B, Ondeck M, Lorenz RR, Prendes B, Ku J, Lamarre E, Scharpf J, Silver NL, Schwartzman L, Geiger JL, Woody NM, Campbell SR, Koyfman SA, Yilmaz E. Immunotherapy response in patients with cutaneous squamous cell carcinoma of head and neck with cranial nerve involvement. *Head Neck.* 2023 Aug;45(8):2149-2154. doi: 10.1002/hed.27419. Epub 2023 Jun 5. PMID: 37272705.
24. Delgado Sillero I, **Lopetegui Lia N**, Sánchez Cousido LF, Rojas Piedra M, Távora Silva B, Garrido Onecha ML, Medina Valdivieso S, Alonso Horcajo N, Díez Tascón C, López González A, Castañón López C, Pedraza Lorenzo M, García Palomo A, Martín V, Diz Tain P. EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain. *J Oncol Pharm Pract.* 2023 Jun;29(4):854-860. doi: 10.1177/10781552221085253. Epub 2022 Mar 21. PMID: 35306915.
25. **Nguyen MT**, Nguyen T, Tran T. Learning to discover medicines. *Int J Data Sci Anal.* 2022 Nov 18:1-16. doi: 10.1007/s41060-022-00371-8. Epub ahead of print. PMID: 36440369; PMCID: PMC9676887.
26. **Jayakrishnan T**, Nair KG, Kamath SD, Wei W, Estfan BN, Krishnamurthi SS, Khorana AA. Comparison of characteristics and outcomes of young-onset versus average onset pancreatico-biliary adenocarcinoma. *Cancer Med.* 2023 Mar;12(6):7327-7338. doi: 10.1002/cam4.5418. Epub 2023 Jan 9. Erratum in: *Cancer Med.* 2023 Jul;12(14):15762. PMID: 36621839; PMCID: PMC10067060.
27. Samhouri Y, **Jayakrishnan TT**, Alnimer L, Bakalov V, Wegner RE, Khan C, Fazal S, Lister J. Treatment Selection and Survival in Patients with Gray Zone Lymphoma: A Comprehensive Population-Based Analysis. *Hematol Oncol Stem Cell Ther.* 2023 Apr 4;16(3):245-253. doi: 10.56875/2589-0646.1045. PMID: 37023222.
28. Samhouri Y, **Jayakrishnan TT**, Alnimer L, Bakalov V, Wegner RE, Khan C, Fazal S, Lister J. Treatment Selection and Survival in Patients with Gray Zone Lymphoma: A Comprehensive Population-Based Analysis. *Hematol Oncol Stem Cell Ther.* 2023 Apr 4;16(3):245-253. doi: 10.56875/2589-0646.1045. PMID: 37023222.
29. Cherico AS, Rizvi A, **Jayakrishnan T**, Mewawalla P. Macroglossia as the initial presentation of AL amyloidosis: review and updates in treatment. *BMJ Case Rep.* 2022 Jul 11;15(7):e249737. doi: 10.1136/bcr-2022-249737. PMID: 35817492; PMCID: PMC9274533.

30. Vusqa U, **Jaykrishnan TT**, Bakalov V, Chahine Z, Wegner R, Khan C, Fazal S, Samhoury Y, Malayala SV, Lister J. Predictors and Long-Term Outcomes for Diffuse Large B-Cell Lymphoma (DLBCL) Patients Undergoing Surgery Prior to Systemic Therapy: A Nationwide Analysis. *Cureus*. 2022 Apr 24;14(4):e24448. doi: 10.7759/cureus.24448. PMID: 35637830; PMCID: PMC9128759.
31. Ashruf OS, Mirzai S, **George LL**, Anwer F. Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges. *Int J Hematol Oncol*. 2023 Feb 24;12(2):IJH44. doi: 10.2217/ijh-2022-0006. PMID: 37304326; PMCID: PMC10248588.
32. Mohamed A, Kruse M, **Tran J**. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer. *Expert Rev Anticancer Ther*. 2023 Jul-Dec;23(10):1071-1084. doi: 10.1080/14737140.2023.2262764. Epub 2023 Oct 26. PMID: 37747062.
33. **Tran J**, Thaper A, Lopetegui-Lia N, Ali A. Locoregional recurrence in triple negative breast cancer: past, present, and future. *Expert Rev Anticancer Ther*. 2023 Jul-Dec;23(10):1085-1093. doi: 10.1080/14737140.2023.2262760. Epub 2023 Oct 26. PMID: 37750222.
34. Valente SA, ElSherif A, **Tran J**, Tu C, Kruse M. Inflammatory breast cancer and the importance of skin punch biopsy. *Am J Surg*. 2023 Mar;225(3):549-552. doi: 10.1016/j.amjsurg.2022.11.017. Epub 2022 Nov 12. PMID: 36437120.
35. **Trunk AD**, Patel SS, Prchal JT, Sborov DW, Zander AR, Lee CJ. Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide. *Leuk Res Rep*. 2023 Aug 26;20:100388. doi: 10.1016/j.lrr.2023.100388. PMID: 37701906; PMCID: PMC10493243.
36. Gerratana L, Davis AA, **Velimirovic M**, Reduzzi C, Clifton K, Bucheit L, Hensing WL, Shah AN, Pivetta T, Dai CS, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Ma CX, Puglisi F, Bardia A, Cristofanilli M. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. *JCO Precis Oncol*. 2023 May;7:e2200531. doi: 10.1200/PO.22.00531. PMID: 37141549; PMCID: PMC10309576.
37. Gerratana L, Davis AA, **Velimirovic M**, Clifton K, Hensing WL, Shah AN, Dai CS, Reduzzi C, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Puglisi F, Ma CX, Bardia A, Cristofanilli M. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis. *Breast Cancer Res*. 2023 Oct 2;25(1):112. doi: 10.1186/s13058-023-01718-0. PMID: 37784176; PMCID: PMC10546685.

### **Poster Presentations/Abstracts**

1. **Brooks T**, Agrima M, Hamilton B, et. al. Cell Product Differences on Incidence of Venous Thromboembolism in Patients Treated with CAR T-Cells for Aggressive B Cell Lymphomas. 2023 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Orlando, FL. February 2023 (Poster)

2. **Curley T**, Wei W, Cordova C, et. al. A Retrospective Study of Patient Characteristics, Treatment Patterns and Outcomes in Patients with Primary CNS Lymphoma. ASH Annual Meeting. San Diego, CA. December 2023 (Poster)
3. **Delasos L**, Wei W, Khaled H, Pennell N, et. al. Clinical outcomes with pembrolizumab-based therapies in relapsed/refractory NSCLC after chemoradiation and consolidative durvalumab. AACR Annual Meeting. Orlando, FL. April 2023 (Poster)
4. **Delasos L**, Khorrami M, Viswanathan V, et. al. Novel Imaging-Based Radiomics Distinguishes Radiation and Immunotherapy induced Pneumonitis in Stage III NSCLC. SITC 38<sup>th</sup> Annual Meeting. San Diego, CA. November 2023 (Poster)
5. **Dima D**, et. al. Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12 Year Experience at a Large Academic Center. ASH Annual Meeting. San Diego, CA. December 2023 (Poster)
6. **George L**, et. al. Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Frontline Ipilimumab and Nivolumab. ASCO Genitourinary Cancers Symposium. San Francisco, CA. February 2023 (Poster)
7. **Hubben A**, et. al. Platelet-associated Beta-2 Glycoprotein 1 Inhibits Agonist-induced Platelet Activation which is Relieved by Proteolytic Cleavage. HTRS 2023 Scientific Symposium. Orlando, FL. March 2023 (Poster)
8. **Hundal J**, et. al. Receipt of work accommodations related to longer job tenure among working breast cancer survivors. ASCO Quality Care Symposium. Boston, MA. October 2023 (Poster)
9. **Jayakrishnan T**, et. al. Metabolomic differences in young-onset versus average-onset colorectal adenocarcinoma. ASCO Gastrointestinal Cancers Symposium. San Francisco, CA. January 2022 (Poster)
10. **Jayakrishnan T**, et. al. Using a Machine Learning Approach to Study Host-Microbiome Interactions in Early-Onset Colorectal Adenocarcinoma. World Congress on Gastrointestinal Cancer. Barcelona, Spain. June 2023 (Poster)
11. **Trunk A**, et. al. Real-world treatment trends and outcomes in elderly patients with metastatic colorectal cancer in the United States. ASCO Annual Meeting. Chicago, IL. June 2023 (Poster)